Fluidigm Corporation, a South San Francisco life science company focused on “integrated fluidic circuits” that control fluids precisely, said it has raised $37 million so far in its fifth round of venture capital.

The investors include Wasatch Advisors, and its private equity affiliate, Cross Creek Capital, as well as existing investors. The company had previously raised $20.05 million for the round, and the new cash amounts $17 million. Before the fifth round, the company had raised about $100 million.

See the company’s statement here. Here’s a snippet:

Fluidigm recently launched the BioMarkâ„¢ system for real-time qPCR, which consists of instrumentation and specialized IFCs called dynamic arrays and digital arrays. IFCs have the potential to replace microwell plates in many applications because of their greater efficiency. Bioassays are assembled within a microscopic network of channels and valves, eliminating much of the liquid handling that characterizes the current microwell plate-based paradigm.

Fluidigm will use the capital to boost sales and marketing of its BioMark system and TOPAZ® system for protein crystallization and to develop new products in the pipeline.

Previous investors include Versant Ventures, Euclid SR Partners, InterWest Partners, Alloy Ventures, Lehman Brothers Healthcare Fund, Bio*One Capital, Bruce Burrows, Lilly BioVentures, the Invus Group, SightLine Partners, AllianceBernstein and GE Equity.

(Story first published 1/9)